Provided by Tiger Trade Technology Pte. Ltd.

Roundhill GLP-1 & Weight Loss ETF

34.26
+0.40391.19%
Pre-market: 34.420.1553+0.45%08:57 EDT
Volume:9K
Turnover:300.32K
Market Cap:66.13M
PE:- -
High:34.40
Open:33.86
Low:33.86
Close:33.86
52wk High:37.15
52wk Low:25.24
Shares:1.93M
Float Shares:1.93M
Volume Ratio:0.46
T/O Rate:0.45%
Dividend:0.41
Dividend Rate:1.20%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

2026 Health Industry Summit Explores Pharmacy Evolution: From Drug Retailers to Community Wellness Hubs

Stock News
·
Aug 13

Novo CEO Says Obesity Market Won't be Winner-Take-All Battle with Lilly

Reuters
·
Aug 13

Pfizer (PFE) Could Be 10% Undervalued Following Raised Revenue Guidance

Simply Wall St.
·
Aug 13

Berenberg Adjusts Price Target on Eli Lilly to $1,220 From $1,135, Maintains Hold Rating

MT Newswires Live
·
Aug 13

Valneva Falls After H1 Revenue, Operating Profit Drop

Reuters
·
Aug 13

Eli Lilly : Berenberg Raises Target Price to $1220 from $1135

THOMSON REUTERS
·
Aug 13

Valneva H1 FY26 Net Loss Widens to EUR 63.28 Million; Revenue Drops 32.51% to EUR 65.84 Million

Reuters
·
Aug 13

Gamco Investors’ Mario Gabelli Ups Stake in Eli Lilly

TIPRANKS
·
Aug 13

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 13

Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)

TIPRANKS
·
Aug 13

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly Over Weight-Loss Drug Ads

MT Newswires Live
·
Aug 13

Kailera Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Health Care Roundup: Market Talk

Dow Jones
·
Aug 13

Pfizer Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Aug 13

Novo Nordisk (NVO) Stock Still Looks Cheap On Earnings But Faces Growth Doubts

Simply Wall St.
·
Aug 13

Kailera Q2 FY26 Net Loss Widens to $111.31 Million; R&D Expenses Climb to $101.06 Million

Reuters
·
Aug 13

Pfizer CEO Albert Bourla Acquires $1,000,920 of Common Shares

Reuters
·
Aug 13

Kailera Therapeutics - Phase 2B High-Dose Ribupatide Injection Trial Fully Enrolled; Data Expected Mid-2027

THOMSON REUTERS
·
Aug 13

Kailera Therapeutics - Ind Application for Ribupatide Oral Active with FDA; Phase 3 Obesity Trials Planned First Half 2027

THOMSON REUTERS
·
Aug 13

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Aug 13